AU762968B2 - Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood - Google Patents

Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood Download PDF

Info

Publication number
AU762968B2
AU762968B2 AU34526/00A AU3452600A AU762968B2 AU 762968 B2 AU762968 B2 AU 762968B2 AU 34526/00 A AU34526/00 A AU 34526/00A AU 3452600 A AU3452600 A AU 3452600A AU 762968 B2 AU762968 B2 AU 762968B2
Authority
AU
Australia
Prior art keywords
composition
igf
accordance
group
lycopene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34526/00A
Other versions
AU3452600A (en
Inventor
Joseph M. Levy
Yoav Sharoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lycored Ltd
Original Assignee
Lycored Natural Products Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lycored Natural Products Industries Ltd filed Critical Lycored Natural Products Industries Ltd
Publication of AU3452600A publication Critical patent/AU3452600A/en
Application granted granted Critical
Publication of AU762968B2 publication Critical patent/AU762968B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/40—Colouring or decolouring of foods
    • A23L5/42—Addition of dyes or pigments, e.g. in combination with optical brighteners
    • A23L5/43—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives
    • A23L5/44—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives using carotenoids or xanthophylls
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Description

WO 00/61130 PCT/IL00/00195 COMPOUNDS USEFUL IN REDUCING THE LEVEL OF INSULIN LIKE GROWTH FACTOR -1 (IGF-1) IN BLOOD Field of the Invention This invention relates to pharmaceutical and dietary compositions comprising a combination of compounds useful in preventing cancer and to the use of said compositions and said combination of compounds for said purpose. This invention more particularly relates to a pharmaceutical or dietary composition for lowering the plasma level of insulin-like growth factor I (IGF-I) levels in mammals.
Background of the Invention The IGF-I level was found to be a major risk factor for prostate (Chan Stampfer Giovannucci Gann Winkinson Hannekens and Pollak M.
"Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study," Science. 279:563-566, 1998) and breast cancer (Hankinson Willett Colditz Hunter Michaud Deroo Rosner Speizer and Pollak M.
"Circulating concentrations of insulin-like growth factor-I and risk of breast cancer," Lancet. 351: 1396-1397, 1988). It is believed that the level of this growth factor in the human circulation is related directly to the risk for these and other malignancies.
Carotenoids are colored pigments with lipophilic properties, widely distributed in fruits and vegetables P-carotene in carrots and lycopene in tomatoes) and active in interfering with IGF-I action (Unpublished results). Carotenoids are transported within circulating lipoproteins when ingested in the human body.
Carotenoids consumption was shown in previous epidemiological studies to be associated with reduced cancer mortality, although recent data did not demonstrate similar beneficial effects (see Hennekens Buring Manson Stampfer Rosier Cook Belanger LaMotte Gaziano Ridker Willet W. and Peto "Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease" Engl. J. Med. 1996; 334: 1145-1149).
Data on the ability of p-carotene supplementation in vitro or in vivo to protect from cancer are conflicting: Some studies found an inhibitory effect of P-carotene supplementation, whereas several others did not find such an effect.
Lycopene, the open chain analog of P-carotene, shares with it a similar structure comprising extended conjugated double bonds. In human plasma, lycopene and P-carotene are quantitatively the major carotenoids. Lycopene was shown to possess the greatest quenching ability of singlet oxygen among the various carotenoids (DiMascio Kaiser S. and Sies "Lycopene as the most efficient biological carotenoid singlet oxygen quencher," Arch. Biochem. Biophys., 1989, 274: 532-538) and it was shown to be at least twice as effective an antoxidant as P-carotene in protecting blood lymphocytes from NO 2 radical damage (Bohm Tinkler and Truscott T.G., "Carotenoids protect against cell membrane damage by the nitrogen dioxide radical," Nature Medicine, 1995, 2: 98-99).
Lycopene has been shown to significantly reduce IGF-induced tyrosine phosphorylation of insulin receptor substrate-I and up-regulation of binding capacity of the AP-I transcription complex (Karas et al. 2000. Nutr. Cancer 36(1): 101-111). However, until now lycopene has not been shown to cause a decrease in the plasma levels of IGF-I.
It would be desirable to provide a pharmaceutical or dietary.composition or preparation comprising a combination of compounds including lycopene and other carotenoids that is effective in reducing plasma IGF-I levels with the attending beneficial effects. It is another purpose of this invention to provide such a composition or preparation that is 25 based on carotenoids, though it does not consist exclusively of carotenoids.
It is a further desirability of this invention to provide such a composition or preparation that comprises products that are acceptable and desirable components of the human diet.
Summary of the Invention The present invention is based on the discovery that there is an unexpected and surprising reduction in plasma levels of insulin like growth factor-I (IGF-I) after lycopene or other carotenoid supplementation in mammals. Accordingly, the present invention provides a pharmaceutical or dietary composition which comprises a carotenoid selected from, but not limited to, a group comprising of lycopene, alpha-, beta-, zeta-carotene, phytoene, phytofluene, lutein, zeaxanthin, cryptoxanthin astaxantine and mixtures thereof, wherein said composition is effective in reducing IGF-I levels in plasma in a mammal. The present invention further provides a use of a carotenoid selected from, but not limited to, a group comprising of lycopene, alpha-, beta-, zeta-carotene, phytoene, phytofluene, lutein, zeaxanthin, cryptoxanthin and astaxantine and mixtures thereof in the preparation of a pharmaceutical or dietary composition which is effective in reducing IGF-I levels in plasma in a mammal.
15 Furthermore, the present invention provides a method for reducing IGF-I levels in plasma in a mammal wherein said method comprises administering to a mammal in need thereof, an IGF-I reducing effective amount of a carotenoid selected from, but not Slimited to, a group comprising of lycopene, alpha-, beta-, zeta-carotene, phytoene, phytofluene, lutein, zeaxanthin, cryptoxanthin and astaxantine and mixtures thereof Thus according to an aspect of the present invention as claimed there is provided a pharmaceutical or dietary composition for lowering the level of IGF-I in blood of mammals which consists of an IGF-I reducing effective amount of tomato oleoresin.
S 25 According to another aspect of the present invention as claimed there is provided use in Saccordance with Claim 5 wherein the unit dose of said composition comprises at least about 3 mg of lycopene.
According to another aspect of the present invention as claimed there is provided a method for lowering the level of IGF-I in the blood of mammals in need thereof which comprises administering an effective amount of tomato oleoresin to said mammal.
P:\WPDOCSom\s'\7646820.sp,.do -3A- Detailed Description of the Invention The following description is illustrative of preferred embodiments of the invention. The following description is not to be construed as limiting, it being understood that the skilled person may carry out many obvious variations to the invention.
The carotenoids referred to throughout the specification are from natural or synthetic sources or from genetically modified organisms.
The invention comprises a method for reduction in plasma level of IGF-I which comprises administering to a patient lycopene or a carotenoid selected from, but not limited to, a group comprising of alpha-, beta-, zeta-carotene; phytoene, phytofluene, *9 e *o o* o *o o *e *e *oo o •oooo WO 00/61130 PCT/IL00/00195 lutein, zeaxanthin, cryptoxanthin astaxantine and mixtures thereof, in the amount of at least 3 mg per day.
Lycopene is a natural product and is present in tomatoes in various concentrations, but it can also be produced synthetically, and synthetic lycopene, compositions comprising it and their use are comprised in the present invention. The composition may contain other dietary components, additives, excipients, binding agents, coatings, etc., or other compounds that have no significant effect in reducing IGF-I. The compositions according to the invention, in view of their purpose, are pharmaceutical composition.
However, since their components are individually acceptable ingredients of the human diet, and, in fact, are individually present in foodstuffs, they may be considered and used as dietary or health compositions.
Tomato oleoresin comprises a combination of lycopene with vitamin E, 0-carotene, phytoene and phytofluene, and therefore the use of tomato oleoresin for the reduction of plasma levels of insulin like growth factor I is a specific aspect of the present invention.
Both tomato oleoresin and pure lycopene reduce plasma levels of IGF-I by at least in responding individuals.
In a preferred way of carrying out the invention, and in the example that will be described, lycopene was obtained from tomato oleoresin. The oleoresin was supplied by LycoRed Natural Products Industries, Ltd., Beer Sheva, Israel. It contained crystalline lycopene suspended in the lipid phase of the tomato. Fatty acids as triglycerides constituted the major part of the oleoresin, whereas 19% were non-saponified materials including inter alia 5% lycopene, 0.1% P-carotene, 1% vitamin E, as well as phytoene and phytofluene. The lycopene used was extracted and purified mainly in the all-trans configuration. Lycopene can be extracted from tomato oleoresin, known in the art by crystallization followed by filtration.
According to a further preferred embodiment of the present invention carotenoids selected from, but not limited to, a group comprising of lycopene, alpha-, beta-, zeta-carotene, phytoene, phytofluene, lutein, zeaxanthin, cryptoxanthin and astaxantin and mixtures thereof are used in the preparation of pharmaceutical or dietary WO 00/61130 PCT/IL00/00195 compositions effective in reducing IGF-I levels in mammalian plasma. The compositions are prepared according to common practices wherein a carotenoid in the amount of at least 3 mg is added to the composition.
According to yet a further preferred embodiment of the present invention a pharmaceutical or dietary composition for lowering IGF-I levels in mammalian blood is provided, wherein said composition is characterized in that it comprises a carotenoid selected from, but not limited to, a group comprising of lycopene, alpha-, beta-, zeta-carotene, phytoene, phytofluene, lutein, zeaxanthin, cryptoxanthin and astaxantin and mixtures thereof. Said composition may be prepared according to common practices well known in the art wherein a carotenoid or a mixture thereof are added to the composition.
EXAMPLE
Example 1: Effect of tomato oleoresin supplementation on plasma levels of IGF-1 The effect of lycopene supplementation on IGF-I blood levels in patients undergoing elective hemorrhoidectomy was studied. Lycopene in tomato oleoresin, two 15 mg capsules per day) or a placebo were administered for three to four weeks prior to surgery. Lycopene concentration and isomer distribution in blood and in the excised tissues were measured by HPLC. Lycopene blood levels increased in most of the subjects who received lycopene supplementation. In the placebo group, the lycopene plasma level before supplementation was similar to that of the lycopene treated group and did not change significantly after supplementation. IGF-I level was measured using the IRMA kit (DSL-5600 Active. Diagnostic System Laboratories, Webster, TX). Basal IGF-I plasma levels varied considerably between subjects. In 15 out of 28 patients in the lycopene-treated group IGF-I blood level decreased by more than 10%. In 7 patients there was no change. In contrast, only 4 out of 28 placebo-treated patients exhibited a decrease in IGF-I plasma level and in 20 no change was occurred. These data clearly indicate lycopene supplementation is effective in significantly reducing IGF-1 levels in a certain proportion of subjects who are "responders". In contrast, when the effects of lycopene supplementation on blood levels of IGF-II and IGF-BP-3 were examined, no differences were found between the lycopene treated group and the placebo group. IGF-II was measured by ELIZA (DSL-10-91000) and IGF-BP-3 by IRMA (DSL-6600), using kits from Diagnostic System Laboratories, Webster, TX.
While embodimerts of the invention and experimental data have been described by way of illustration, it should be understood that the invention is not limited thereto and may be carried out with many modifications, variations and adaptations, without departing from its spirit or exceeding the scope of the claims.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers or steps but not the exclusion of any other integer or group of integers or steps.
The reference to any prior art in this specification is not, and should not be taken as, an acknowledgement or any form of suggestion that the prior art forms part of the common general knowledge in Australia.
*oo*

Claims (13)

1. A pharmaceutical or dietary composition for lowering the level of IGF-I in blood of mammals which consists of an IGF-I reducing effective amount of tomato oleoresin.
2. A composition in accordance with Claim 1 wherein the unit dose of said composition comprises at least about 3 mg of tomato oleoresin.
3. A composition in accordance with Claim 1 or Claim 2 wherein the composition contains compounds selected from the group comprising dietary components, additives, excipients, binding agents, coatings, preservatives, and mixtures thereof. oooo
4. A composition in accordance with any one of Claims 1 to 3 wherein the composition is contained in dosage forms selected from the group comprising tablets, caplets, vegecaps and hard shell gelatin capsules.
Use of a tomato oleoresin for the preparation of pharmaceutical or dietary compositions for lowering the level of IGF-I in the blood of mammals and the prevention of cancer.
6. Use in accordance with Claim 5 wherein the unit dose of said composition comprises at least about 3 mg of lycopene.
7. A use in accordance with any one of Claims 5 to 6 wherein the composition contains compounds selected from the group comprising dietary components, additives, excipients, binding agents, coatings, preservatives, and mixtures thereof.
8. A use in accordance with any one of Claims 5 to 7 wherein the composition is contained in dosage forms selected from the group comprising tablets, caplets, vegecaps and hard shell gelatin capsules. P:\WPDOCS socp\V\7646820.spe.d.-3 1/3/03 8
9. A method for lowering the level of IGF-I in the blood of mammals in need thereof which comprises administering an effective amount of tomato oleoresin to said mammal.
A method in accordance with Claim 9 wherein the unit dose of said composition comprises at least about 3 mg of lycopene.
11. A method in accordance with either Claim 9 or Claim 10 wherein the composition contains compounds selected from the group comprising of dietary components, additives, excipients, binding agents, coatings, preservatives, and mixtures thereof.
12. A method in accordance with any one of Claims 9 to 11 wherein the composition is contained in dosage forms selected from the group comprising tablets, caplets, vegecaps and hard shell gelatin capsules.
13. Pharmaceutical compositions or uses/methods involving/containing same, substantially as hereinbefore described with reference to the Examples. DATED this 31st day of March, 2003 LYCORED NATURAL PRODUCTS INDUSTRIES LTD By its Patent Attorneys DAVIES COLLISON CAVE ooo•.
AU34526/00A 1999-04-14 2000-03-29 Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood Ceased AU762968B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12944299A IL129442A0 (en) 1999-04-14 1999-04-14 Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood
IL129442 1999-04-14
PCT/IL2000/000195 WO2000061130A1 (en) 1999-04-14 2000-03-29 Compounds useful in reducing the level of insulin like growth factor-1 (igf-1) in blood

Publications (2)

Publication Number Publication Date
AU3452600A AU3452600A (en) 2000-11-14
AU762968B2 true AU762968B2 (en) 2003-07-10

Family

ID=11072705

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34526/00A Ceased AU762968B2 (en) 1999-04-14 2000-03-29 Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood

Country Status (9)

Country Link
EP (1) EP1173158A1 (en)
JP (1) JP2002541193A (en)
CN (1) CN1355695A (en)
AU (1) AU762968B2 (en)
BR (1) BR0011171A (en)
CA (1) CA2369084A1 (en)
IL (1) IL129442A0 (en)
RU (1) RU2242220C2 (en)
WO (1) WO2000061130A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135335A (en) * 2000-03-29 2013-12-31 Lycored Natural Prod Ind Ltd Use of carotenoids in the preparation of medicaments for preventing hormone induced adverse effects and pharmaceutical compositions comprising carotenoids
WO2005112904A1 (en) * 2004-05-20 2005-12-01 Arkray, Inc. Peroxisome proliferator-activated receptor (ppar) activator and drugs, supplements, functional foods and food additives using the same
US8460718B2 (en) * 2011-04-07 2013-06-11 Lycored Ltd. Synergistic compositions and methods
JP5559406B2 (en) * 2013-09-11 2014-07-23 株式会社 資生堂 Method for evaluating the probability of having a stain
CN116268416A (en) * 2023-04-28 2023-06-23 西藏多欣健康科技有限公司 Composition containing maltodextrin and crystalline fructose and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302421A2 (en) * 1987-07-30 1989-02-08 Lion Corporation Alpha-carotene for inhibiting the growth of cancer cells
EP0600544A1 (en) * 1992-11-30 1994-06-08 Makhteshim Chemical Works Limited Use of lycopene for reducing the activity of cells, especially of cancer cells, and pharmaceutical preparations
US5328845A (en) * 1992-03-27 1994-07-12 Universal Foods Corporation Fungal negative microorganism capable of producing high levels of beta-carotene

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2629856B2 (en) * 1987-07-30 1997-07-16 ライオン株式会社 Antitumor agent
IL110139A0 (en) * 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
JPH09124470A (en) * 1995-10-26 1997-05-13 Suntory Ltd Antistress composition
JPH10212228A (en) * 1996-11-27 1998-08-11 Dainippon Ink & Chem Inc Carcinogenesis or neoplasm metastasis inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302421A2 (en) * 1987-07-30 1989-02-08 Lion Corporation Alpha-carotene for inhibiting the growth of cancer cells
US5328845A (en) * 1992-03-27 1994-07-12 Universal Foods Corporation Fungal negative microorganism capable of producing high levels of beta-carotene
EP0600544A1 (en) * 1992-11-30 1994-06-08 Makhteshim Chemical Works Limited Use of lycopene for reducing the activity of cells, especially of cancer cells, and pharmaceutical preparations

Also Published As

Publication number Publication date
CA2369084A1 (en) 2000-10-19
CN1355695A (en) 2002-06-26
WO2000061130A1 (en) 2000-10-19
RU2242220C2 (en) 2004-12-20
AU3452600A (en) 2000-11-14
JP2002541193A (en) 2002-12-03
BR0011171A (en) 2003-07-29
IL129442A0 (en) 2000-02-29
EP1173158A1 (en) 2002-01-23

Similar Documents

Publication Publication Date Title
Alves-Rodrigues et al. The science behind lutein
Krinsky et al. Carotenoids in health and disease
Voutilainen et al. Carotenoids and cardiovascular health
RU2459617C2 (en) Synergetic combinations for treating hypertension
Riccioni Carotenoids and cardiovascular disease
US7887847B2 (en) Nutritional supplement for treatment of ocular diseases
Shegokar et al. Carotenoid lutein: a promising candidate for pharmaceutical and nutraceutical applications
US6362221B1 (en) Compositions containing natural lycopene and natural tocopherol
EP1470817A1 (en) Compositions for preventing human cancer and method of preventing human cancer
NZ309130A (en) A pharmaceutical composition containing meso-zeaxanthin optionally with lutein
JP2003516720A (en) Stable carotene-xanthophyll beadlet compositions and methods of use
TWI351277B (en) Compositions containing reduced coenzyme q10 and c
JP2002522382A (en) Antioxidant, antiproliferative composition comprising carnitine and carotenoid
AU762968B2 (en) Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood
AU772825B2 (en) Sunscreen agent for oral administration
AU705467B2 (en) Pharmaceutical compositions comprising lycopene
JP2002504928A (en) Natural composition for preventing LDL oxidation
Challem Beta-carotene and other carotenoids: promises, failures, and a new vision
US20220175693A1 (en) Dietary supplement comprising lutein for telomere protection, and method for production thereof
Naguib Carotenoids come of age
Lewerissa Carotenoids and Their Health Benefits
LAI FREDERICK KHACHIK FREDERICK B. ASKIN
JPWO2017195504A1 (en) Blood carotenoid balance improver
Sharoni Joseph Levy, Michael Danilenko, Michael Karas, Hadar Amir, Amit Nahum, Yudit Giat and
MXPA01000874A (en) Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)